$288 Million is the total value of Krensavage Asset Management, LLC's 10 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 23.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| UTHR | Sell | UNITED THERAPEUTICS CORP | $44,256,000 | +15.7% | 204,812 | -1.2% | 15.35% | +27.9% |
| REGN | Sell | REGENERON PHARMACEUTICALS | $43,625,000 | -1.4% | 69,080 | -5.6% | 15.13% | +9.0% |
| ENTA | Sell | ENANTA PHARMACEUTICALS INC | $42,184,000 | -20.7% | 564,102 | -39.8% | 14.63% | -12.4% |
| MCK | Sell | MCKESSON CORP | $38,882,000 | +18.5% | 156,424 | -5.0% | 13.49% | +31.0% |
| ALKS | Buy | ALKERMES PLC | $33,563,000 | -24.5% | 1,442,965 | +0.1% | 11.64% | -16.6% |
| EXEL | Buy | EXELIXIS INC | $28,464,000 | +34.6% | 1,557,119 | +55.7% | 9.87% | +48.9% |
| TARO | Sell | TARO PHARMACEUTICAL INDUS | $27,008,000 | -22.2% | 538,967 | -1.2% | 9.37% | -14.0% |
| BIIB | Sell | BIOGEN INC | $24,724,000 | -15.3% | 103,053 | -0.1% | 8.58% | -6.4% |
| EGRX | Sell | EAGLE PHARMACEUTICALS INC | $5,422,000 | -9.8% | 106,487 | -1.2% | 1.88% | -0.3% |
| NXTC | Buy | NEXTCURE INC | $186,000 | -10.6% | 31,027 | +0.3% | 0.06% | 0.0% |
| TVTX | Exit | TRAVERE THERAPEUTICS INC | $0 | – | -137,203 | -100.0% | -1.04% | – |
| IVC | Exit | INVACARE CORP | $0 | – | -891,259 | -100.0% | -1.33% | – |
| SRGA | Exit | SURGALIGN HOLDINGS INC | $0 | – | -6,332,945 | -100.0% | -2.16% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITED THERAPEUTICS CORP | 36 | Q3 2023 | 18.1% |
| Enanta Pharmceuticals Inc | 35 | Q3 2023 | 16.7% |
| INVACARE CORP | 28 | Q3 2021 | 5.8% |
| RTI SURGICAL INC | 23 | Q2 2020 | 7.9% |
| MCKESSON CORP | 20 | Q3 2022 | 16.3% |
| BIOGEN INC | 19 | Q3 2023 | 16.0% |
| MERCK & CO. INC. | 18 | Q1 2019 | 11.1% |
| DIGIRAD CORP | 18 | Q1 2019 | 1.0% |
| REGENERON PHARMACEUTICALS | 16 | Q3 2023 | 16.1% |
| ALKERMES PLC | 16 | Q3 2023 | 14.1% |
View Krensavage Asset Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SURGALIGN HOLDINGS, INC. | February 19, 2021 | 5,380,449 | 6.6% |
| RTI SURGICAL, INC. | February 14, 2019 | 3,852,567 | 6.1% |
| Aviragen Therapeutics, Inc. | February 15, 2018 | 2,292,058 | 5.9% |
| ENANTA PHARMACEUTICALS INC | February 15, 2017 | 883,902 | 4.6% |
| Biota Pharmaceuticals, Inc. | February 17, 2016 | 2,267,655 | 5.9% |
View Krensavage Asset Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SCHEDULE 13G | 2024-02-27 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-15 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-16 |
| 13F-HR | 2023-02-15 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-17 |
| 13F-HR | 2022-02-15 |
View Krensavage Asset Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.